EyePoint Management
Management criteria checks 2/4
EyePoint's CEO is Jay Duker, appointed in Jan 2023, has a tenure of 3.08 years. total yearly compensation is $5.95M, comprised of 11.2% salary and 88.8% bonuses, including company stock and options. directly owns 0.21% of the company’s shares, worth $2.39M. The average tenure of the management team and the board of directors is 3.9 years and 4.5 years respectively.
Key information
Jay Duker
Chief executive officer
US$6.0m
Total compensation
| CEO salary percentage | 11.24% |
| CEO tenure | 3.1yrs |
| CEO ownership | 0.2% |
| Management average tenure | 3.9yrs |
| Board average tenure | 4.5yrs |
Recent management updates
Recent updates
After Leaping 38% EyePoint, Inc. (NASDAQ:EYPT) Shares Are Not Flying Under The Radar
Dec 12
EyePoint: Uncompelling Non-Inferiority Strategy Vs. A Moving Aflibercept Target
Oct 16EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Looks Just Right With A 32% Price Jump
Sep 06After Leaping 47% EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Are Not Flying Under The Radar
Jun 16Is EyePoint Pharmaceuticals (NASDAQ:EYPT) In A Good Position To Invest In Growth?
May 03
DURAVYU Phase III Trials Will Accelerate Market Entry
Expedited Phase III trial progress and robust patent protection could maximize long-term revenue and margin potential for DURAVYU.EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Full-Year Results: Here's What Analysts Are Forecasting For This Year
Mar 09EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
Feb 26EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival
Jan 30EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) 29% Share Price Plunge Could Signal Some Risk
Dec 13EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity
Nov 14Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52%
Oct 29EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price
Sep 13EyePoint Pharmaceuticals - After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)
Aug 29These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Aug 15EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 09Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%
Jun 19EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)
May 06More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%
Mar 31EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time
Feb 20Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%
Feb 05Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?
Jan 29Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking
Dec 18These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Dec 13Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
May 14Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking
Apr 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$206m |
| Jun 30 2025 | n/a | n/a | -US$175m |
| Mar 31 2025 | n/a | n/a | -US$147m |
| Dec 31 2024 | US$6m | US$670k | -US$131m |
| Sep 30 2024 | n/a | n/a | -US$104m |
| Jun 30 2024 | n/a | n/a | -US$87m |
| Mar 31 2024 | n/a | n/a | -US$79m |
| Dec 31 2023 | US$3m | US$614k | -US$71m |
| Sep 30 2023 | n/a | n/a | -US$100m |
| Jun 30 2023 | n/a | n/a | -US$106m |
| Mar 31 2023 | n/a | n/a | -US$102m |
| Dec 31 2022 | US$2m | US$515k | -US$102m |
| Sep 30 2022 | n/a | n/a | -US$78m |
| Jun 30 2022 | n/a | n/a | -US$77m |
| Mar 31 2022 | n/a | n/a | -US$67m |
| Dec 31 2021 | US$3m | US$269k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$54m |
| Jun 30 2021 | n/a | n/a | -US$42m |
| Mar 31 2021 | n/a | n/a | -US$44m |
| Dec 31 2020 | US$53k | n/a | -US$45m |
| Sep 30 2020 | n/a | n/a | -US$40m |
| Jun 30 2020 | n/a | n/a | -US$52m |
| Mar 31 2020 | n/a | n/a | -US$51m |
| Dec 31 2019 | US$80k | n/a | -US$57m |
Compensation vs Market: Jay's total compensation ($USD5.95M) is above average for companies of similar size in the US market ($USD3.39M).
Compensation vs Earnings: Jay's compensation has increased whilst the company is unprofitable.
CEO
Jay Duker (66 yo)
Dr. Jay S. Duker, M.D., co-founded Hemera Biosciences Inc. and serves as its Executive Director. He serves as Member of Retina Segment Scientific Advisory Board at Aldeyra Therapeutics, Inc. Dr. Duker is t...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.1yrs | US$5.95m | 0.21% $ 2.4m | |
| Executive VP & CFO | 6.3yrs | US$3.20m | 0.14% $ 1.6m | |
| Chief Medical Officer | 1.9yrs | US$3.53m | 0% $ 0 | |
| Chief Scientific Officer | 1.1yrs | no data | no data | |
| Chief Legal Officer & Company Secretary | 7.3yrs | no data | no data | |
| Chief People Officer & Senior VP of IT | 7.1yrs | no data | no data | |
| Senior VP & Chief Commercial Officer | 6.7yrs | US$1.46m | no data | |
| Chief Regulatory Officer | 3.9yrs | no data | no data | |
| Chief Manufacturing Officer | 1.2yrs | no data | no data | |
| CEO of AION Diagnostics Ltd | no data | US$225.94k | no data |
Experienced Management: EYPT's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.6yrs | US$5.95m | 0.21% $ 2.4m | |
| CEO of AION Diagnostics Ltd | no data | US$225.94k | no data | |
| Independent Non-Executive Chairman | 7.7yrs | US$476.43k | 0.016% $ 177.7k | |
| Independent Director | 6.6yrs | US$475.19k | 0.012% $ 134.8k | |
| Vice Chair | 9.4yrs | US$2.06m | 0.51% $ 5.7m | |
| Co- Chairman of Scientific Advisory Board | 4.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.5yrs | no data | no data | |
| Director | 7.3yrs | US$1.38m | 0.026% $ 289.3k | |
| Independent Director | 3.6yrs | US$457.58k | 0.046% $ 520.5k | |
| Co-Chair of Scientific Advisory Board | 4.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.5yrs | no data | no data |
Experienced Board: EYPT's board of directors are considered experienced (4.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/02 09:06 |
| End of Day Share Price | 2026/02/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
EyePoint, Inc. is covered by 19 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Jennifer Kim | Cantor Fitzgerald & Co. |